Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Epigenetic silencing including histone modifications and DNA methylation is an important tumorigenic mechanism. However, its role in cancer immunopathology and immunotherapy is poorly understood. Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, and subsequently determine effector T-cell trafficking to the tumour microenvironment. Treatment with epigenetic modulators removes the repression and increases effector T-cell tumour infiltration, slows down tumour progression, and improves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) checkpoint blockade and adoptive T-cell transfusion in tumour-bearing mice. Moreover, tumour EZH2 and DNMT1 are negatively associated with tumour-infiltrating CD8(+) T cells and patient outcome. Thus, epigenetic silencing of TH1-type chemokines is a novel immune-evasion mechanism of tumours. Selective epigenetic reprogramming alters the T-cell landscape in cancer and may enhance the clinical efficacy of cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epigenetic reprogramming with shRNAs targeting DNA methyltransferase 1 (DNMT1) or pan-DNMT blockers like decitabine and guadecitabine has been shown to resemble EZH2 inhibition in its capacity to promote CXCL9 and CXCL10 secretion in various models of breast, lung, and ovarian carcinoma”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [107]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The mTOR pathway has long been recognized to play a pivotal role in integrating signals at the cellular level and promote autoimmunity and carcinogenesis18,19.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“and TH1 cytokines”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Cited by
Items 301–400 of 1,000
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 84
“Expression of EZH2 in ovarian cancer cells epigenetically repressed production of chemokines CXCL9 and CXCL10 by mediating H3K27me3 (trimethylation of histone H3 lysine 27), which blocked T cell infiltration into the tumor bed.(90) Similar effects were observed with expressing polycomb repressive complex 2 (PRC2) (EZH…”
BackgroundLung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity
Li, L., Yang, L., Cheng, S., Fan, Z., Shen, Z., Xue, W., Zheng, Y., Li, F., Wang, D., Zhang, K., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1027-x · Cited by 76
H3K36 trimethylation-mediated biological functions in cancer
Xiao, C., Fan, T., Tian, H., Zheng, Y., Zhou, Z., Li, S., Li, C., & He, J. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01187-2 · Cited by 63
“Then, innate immune response for tumors is triggered, like IFN-γ associated downstream signaling pathways mediated by doublestrand RNA (dsRNA), thereby enhancing the patients’ response to immunotherapy [139, 140].”
BackgroundEpigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer
Chen, S., Xie, P., Cowan, M. L., Huang, H., Cárdenas, H., Keathley, R., Tanner, E. J., Fleming, G. F., Moroney, J. W., Pant, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158800 · Cited by 88
“Epigenetically repressed Th cell responses could be restored by epigenetic modulators in immunocompetent OC mouse models, in which the response to ICIs was also augmented by this strategy (16).”
DNA methylation and cancer: transcriptional regulation, prognostic, and therapeutic perspective
Bhootra, S., Jill, N., Shanmugam, G., Rakshit, S., & Sarkar, K. (2023) · Medical Oncology · doi:10.1007/s12032-022-01943-1 · Cited by 85
“Low tumor-infiltrating CD8 + T-cell levels and patient outcomes in cancer are correlated with DNA methyltransferases such as DNMT1 and histone methyltransferases, like EZH2 [113].”
BackgroundDual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer
Huang, W., Zhu, Q., Shi, Z., Tu, Y., Li, Q., Zheng, W., Yuan, Z., Li, L., Zu, X., Hao, Y., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01895-7 · Cited by 88
“This response further promotes the production of type I and type III interferons and induces the production of a variety of interferon-stimulated genes (ISGs) and cytokines [19, 22, 23], thereby inhibiting tumour cell immune escape.”
Gounder, M. M., Zhu, G. G., Roshal, L., Lis, E., Daigle, S. R., Blakemore, S. J., Michaud, N. R., Hameed, M., & Hollmann, T. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3133 · Cited by 81
“Tazemetostatmay have induced lymphocyte infiltration of the PCD through reported effects of EZH2 disruption on reprogramming of tumor infiltrating Tregs to stimulate T-cell infiltration (11, 12, 17) or by upregulating chemokine and cytokine expression (15, 19).”
BackgroundHayashi, H., Sugawara, S., Fukuda, Y., Fujimoto, D., Miura, S., Ota, K., Ozawa, Y., Hara, S., Tanizaki, J., Azuma, K., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3194 · Cited by 82
“EGFR 463 signaling thus induces down-regulation of the transcription factor IRF1 concurrently with that 464 of its target gene for CXCL10 through the PI3K-AKT signaling pathway (33).”
BackgroundInfluentialXu, H., Lin, S., Zhou, Z., Li, D., Zhang, X., Yu, M., Zhao, R., Wang, Y., Qian, J., Li, X., et al. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01032-x · Cited by 85
“Combined inhibition of EZH2 and DNMT1 augmented the expression of the inflammatory chemokines CXCL9 and CXCL10, which increased TILs and decreased tumor progression, thus improving the therapeutic efficacy of PDL1 checkpoint blockade and adoptive T-cell transfusion in tumorbearing mice [248].”
BackgroundTelltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer
Lei, Y. L., Xie, Y., Tan, Y. S., Prince, M. E., Moyer, J. S., Nor, J. E., & Wolf, G. T. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.08.003 · Cited by 82
“Epigenetic silencing of TH1 cytokines CXCL9 and CXCL10 in cancer cells severely compromised the recruitment of effector T-cells, and blockade of epigenetic repression improved checkpoint-targeted immunotherapy [58].”
BackgroundCheng, J., Luo, W., Sun, C., Jin, Z., Zeng, X., Alexander, P. B., Gong, Z., Xia, X., Ding, X., Xu, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc7609 · Cited by 78
“In addition, the targeted inhibition of either enhancer of zeste homolog 2 (EZH2)–mediated histone H3 lysine 27 trimethylation (H3K27me3) or DNA methyltransferase 1 (DNMT1)–mediated DNA methylation could enhance sensitivity to the PD-1 blockade, owing to the release of CXCL9 and CXCL10 from tumors (14).”
BackgroundCXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
Seitz, S., Dreyer, T. F., Stange, C., Steiger, K., Bräuer, R., Scheutz, L., Multhoff, G., Weichert, W., Kiechle, M. B., Magdolen, V., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01763-0 · Cited by 82
“Prominent examples include CDK4/6 inhibitors such as abemaciclib [40], epigenetic modulators [41] or PARP inhibitors (PARPi) [42].”
BackgroundEngineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel
Irving, M. B., de Silly, R. V., Scholten, K. B. J., Dilek, N., & Coukos, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00267 · Cited by 80
“org April 2017 | Volume 8 | Article 267 to checkpoint blockade (242).”
BackgroundModulation of the CCR6-CCL20 Axis: A Potential Therapeutic Target in Inflammation and Cancer
Ranasinghe, R., & Eri, R. (2018) · Medicina · doi:10.3390/medicina54050088 · Cited by 74
“The tumor microenvironment is responsible for setting the pace for tumorigenesis, stem cell-like properties expressed by cancer cells, survival, invasiveness, and metastasis of cancer cells [39,40].”
Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
Lodewijk, I., Nunes, S. P., Henrique, R., Jerónimo, C., Dueñas, M., & Paramio, J. M. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01046-0 · Cited by 78
“Various studies described an enhanced effector-T cell infiltration and cytotoxic activation in the TME upon EZH2 inhibition as well as functional alterations of the Treg population resulting in Treg-mediated pro-inflammatory activities [93, 103, 121, 122].”
BackgroundAdvances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment
Andrea, A. E., Chiron, A., Mallah, S., Bessoles, S., Sarrabayrouse, G., & Hacein‐Bey‐Abina, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830292 · Cited by 77
“Furthermore, as CXCR3 and CCR5 are often used by activated T cell to infiltrate tumors that should express their respective ligands (28), an insufficient expression of CXCR3 and CCR5 ligands by some tumors leads to a decrease in T cell recruitment (29, 30).”
BackgroundGranhøj, J. S., Jensen, A. W. P., Presti, M., Met, Ö., Svane, I. M., & Donia, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2064711 · Cited by 82
Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives
Schiffmann, I., Greve, G., Jung, M., & Lübbert, M. (2016) · Epigenetics · doi:10.1080/15592294.2016.1237345 · Cited by 77
“ognition.(7) Table 1 provides a list of currently investigated DNMTi.”
BackgroundTreg programming and therapeutic reprogramming in cancer
Ayala, M. A. M., Li, Z., & DuPage, M. J. P. (2019) · Immunology · doi:10.1111/imm.13058 · Cited by 78
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms
Wang, Y., Mohseni, M., Grauel, A., Diez, J. E., Guan, W., Liang, S., Choi, J. E., Pu, M., Chen, D., Laszewski, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-80999-x · Cited by 73
TCR-engineered T cells to treat tumors: Seeing but not touching?
Debets, R., Donnadieu, E., Chouaïb, S., & Coukos, G. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.002 · Cited by 81
Cai, Z., Chen, J., Yu, Z.-Z., Li, H., Liu, Z., Deng, D., Liu, J., Chen, C., Zhang, C., Ou, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202207155 · Cited by 86
Immune checkpoint inhibitors: new strategies to checkmate cancer
Wilson, R. A. M., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2018) · Clinical and Experimental Immunology · doi:10.1111/cei.13081 · Cited by 70
“These include, but are not limited to, the distribution of the target immune checkpoint protein; the immune cell context within the tumour; the availability, immunogenicity and frequency of tumour antigens; the pharmacodynamics and pharmacokinetics of the ICI; and the amenability of the TME for effective drug delivery…”
BackgroundInfluentialTelli, M. L., Nagata, H., Wapnir, I., Acharya, C. R., Zablotsky, K., Fox, B. A., Bifulco, C. B., Jensen, S. M., Ballesteros‐Merino, C., Le, M. H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3944 · Cited by 77
“Another study supporting the importance of this axis demonstrated that epigenetic silencing of CXCL9/10 was enough to inhibit response to ICI and that modifying this epigenetic suppression could sensitize mice (50).”
BackgroundLin, H., Jeon, A., Chen, K., Lee, C. J. M., Wu, L., Chong, S.-L., Anene-Nzelu, C. G., Foo, R., & Chow, P. K. H. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-02969-8 · Cited by 85
“This repression correlates with reduced in fi ltration of tumor-in fi ltrating lymphocytes and poorer clinical outcomes [203].”
A Blueprint to Advance Colorectal Cancer Immunotherapies
Le, D. T., Hubbard-Lucey, V. M., Morse, M. A., Heery, C. R., Dwyer, A., Marsilje, T. H., Brodsky, A. N., Chan, E., Deming, D. A., Diaz, L. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0375 · Cited by 69
Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes
Matei, D. E., & Nephew, K. P. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3837 · Cited by 72
“Furthermore, in another study, epigenetic silencing through DNA and H3K27 methylation of T-helper-1 (TH1) cytokines CXCL9 and CXCL10 in tumor cells was shown to play a significant role in T-cell trafficking in ovarian tumors, and derepression of this mechanism by using DNA HMAs in combination with histone methyl trans…”
BackgroundSheng, W., Liu, Y., Chakraborty, D., Debo, B. M., & Shi, Y. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0017 · Cited by 78
Epigenetic Modifiers in Immunotherapy: a Focus on Checkpoint Inhibitors
Terranova-Barberio, M., Thomas, S., & Munster, P. N. (2016) · Immunotherapy · doi:10.2217/imt-2016-0014 · Cited by 70
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy
Ghoneim, H. E., Zamora, A. E., Thomas, P. G., & Youngblood, B. A. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.10.002 · Cited by 71
“methyltransferase inhibitors, enhanced CXCL9 and CXCL10 chemokine production and T-cell trafficking into the tumor and potentiated tumor regression following ICB therapy [78, 79].”
BackgroundHepatic IFIT3 predicts interferon‐α therapeutic response in patients of hepatocellular carcinoma
Yang, Y., Zhou, Y., Hou, J., Bai, C., Li, Z., Fan, J., Ng, I. O., Zhou, W., Sun, H., Dong, Q., et al. (2017) · Hepatology · doi:10.1002/hep.29156 · Cited by 74
“Immune checkpoint blockade, T-cell adoptive transfer, together with administration of known cytokine therapy such as interferon-a (IFN-a) have been verified in the clinic to induce durable therapeutic responses in certain cancer patients.((1-4)) However, only a subgroup of patients respond to these immunotherapies, an…”
BackgroundZito Marino, F., Ascierto, P. A., Rossi, G., Staibano, S., Montella, M., Russo, D., Alfano, R., Morabito, A., Botti, G., & Franco, R. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1309387 · Cited by 73
Rajabi, H. N., Hiraki, M., & Kufe, D. W. (2018) · Oncogene · doi:10.1038/s41388-017-0096-9 · Cited by 72
“Immune evasion of tumors has also been associated with EZH2-mediated suppression of chemokines and effector Tcell recruitment [94, 95].”
BackgroundTumor Cell–Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer
Li, J., Yuan, S., Norgard, R. J., Yan, F., Yamazoe, T., Blanco, M. A., & Stanger, B. Z. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0661 · Cited by 75
“These findings expand our understanding of tumorintrinsic epigenetic factors that shape the TME (29, 30) and are in line with a report describing a role for USP22 in regulating the immune microenvironment in liver cancer (13).”
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
Czajka‐Francuz, P., Prendes, M. J., Mankan, A. K., Quintana, Á., Pabla, S., Ramkissoon, S. H., Jensen, T. J., Peiró, S., Severson, E. A., Achyut, B. R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200646 · Cited by 76
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance
Zheng, W., Skowron, K. B., Namm, J. P., Burnette, B., Fernandez, C., Arina, A., Liang, H., Spiotto, M. T., Posner, M. C., Fu, Y.-X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9915 · Cited by 69
“Noteworthy, it was recently reported that epigenetic modulation of CXCL9 and CXCL10 promoted tumor T cell infiltration and enhanced efficacy of PD-L1 blockade [36].”
BackgroundJin, M. L., & Jeong, K. W. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01014-z · Cited by 76
Muthuswamy, R., Corman, J. M., Dahl, K., Chatta, G. S., & Kalinski, P. (2016) · The Prostate · doi:10.1002/pros.23194 · Cited by 69
“1A) revealed only marginal levels of CCL5, CXCL9, and CXCL10, the chemokines implicated in CTL attraction to tumor tissues [32,33,47,48].”
BackgroundLiu, M., Zhou, J., Chen, Z., & Cheng, A. S. L. (2016) · The Journal of Pathology · doi:10.1002/path.4832 · Cited by 73
Kreidieh, M., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2020) · BioMed Research International · doi:10.1155/2020/9037217 · Cited by 80
Impact of epigenetic reprogramming on antitumor immune responses in glioma
McClellan, B. L., Haase, S., Núñez, F. J., Alghamri, M. S., Dabaja, A. A., Lowenstein, P. R., & Castro, M. G. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163450 · Cited by 85
“In addition, EZH2is increase T cell tumor infiltration, decrease tumor growth, and improve the therapeutic efficacy of ICIs in preclinical tumor models (128, 129).”
BackgroundEpigenetic modulation in cancer immunotherapy
Gallagher, S. J., Shklovskaya, E., & Hersey, P. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.006 · Cited by 73
Yuen, V. W., Chiu, D. K., Law, C., Cheu, J. W., Chan, C. Y., Wong, B. P., Goh, C.-C., Zhang, M. S., Xue, H. D. G., Tse, A. P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.037 · Cited by 70
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 79
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
Porazzi, P., Nason, S., Yang, Z., Carturan, A., Ghilardi, G., Guruprasad, P., Patel, R. P., Tan, M. T., Padmanabhan, A. A., Lemoine, J., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.013 · Cited by 80
Smith, J. S., Alagesan, P., Desai, N. K., Pack, T. F., Wu, J., Inoue, A., Freedman, N. J., & Rajagopal, S. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.108522 · Cited by 69
“Aberrant CXCR3 signaling is implicated in inflammatory diseases, inhibition of blood vessel formation, and both tumor repression and tumorigenesis (Kawada et al., 2004; Koch et al., 2009; Villarroel et al., 2014; Peng et al., 2015).”
BackgroundGene-Specific Targeting of DNA Methylation in the Mammalian Genome
Urbano, A., Smith, J., Weeks, R. J., & Chatterjee, A. (2019) · Cancers · doi:10.3390/cancers11101515 · Cited by 72
“For example, in ovarian tumors, immunoprotective genes were shown to be epigenetically silenced, resulting in the repression of T helper 1-type chemokine production [39].”
BackgroundCheckpoint Inhibition in Myeloma: Opportunities and Challenges
Costa, F., Das, R., Bailur, J. K., Dhodapkar, K. M., & Dhodapkar, M. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02204 · Cited by 70
“Several studies suggest a role for genetic and epigenetic modifications in cancer development and progression (4–6) and some of them correlate with the ability to escape this immunosurveillance (5, 6).”
BackgroundSasaki, K., Nishina, S., 山内, 明., Fukuda, K., Hara, Y., Yamamura, M., Egashira, K., & Hino, K. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.10.010 · Cited by 70
“reported to repress the tumor production of CXCL9/ CXCL10.(26) It also has been reported that AMPK phosphory-”
BackgroundAlmawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 78
Dysregulation of C-X-C motif ligand 10 during aging and association with cognitive performance
Bradburn, S., McPhee, J., Bagley, L., Carroll, M., Slevin, M., Al-Shanti, N., Barnouin, Y., Hogrel, J.-Y., Pääsuke, M., Gapeyeva, H., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.11.009 · Cited by 65
Ma, T., Hu, C., Lal, B., Zhou, W., Ma, Y., Ying, M., Prinos, P., Quiñones‐Hinojosa, A., Lim, M. K., Laterra, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2489 · Cited by 67
“Notably, it has been reported that cancer cells negatively regulate CCL5, CXCL9, and CXCL10 expression by epigenetic silencing mechanisms such as DNA methylation (33), which we have reported to be induced byOct4/Sox2 andupregulated inGSCs (8).”
BackgroundExposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
Olino, K. L., Park, T. S., & Ahuja, N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.001 · Cited by 68
Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy
Chen, Y., Li, H., & Fan, Y. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102606 · Cited by 71
Mandal, K., Barik, G. K., & Santra, M. K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02400-z · Cited by 78
Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation
Tang, G., Guo, J., Zhu, Y., Huang, Z., Liu, T., Cai, J., Yu, L., & Wang, Z. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4343 · Cited by 77
“In ovarian cancer, H3K27me3 contributes to the formation of the tumor microenvironment (17), the development of resistance to cisplatin and tumor progression (18).”
BackgroundRole of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment
Yang, Y., & Wang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640369 · Cited by 74
Kim, D. J. (2025) · Current Oncology · doi:10.3390/curroncol32020088 · Cited by 76
“Identifying the fifth base of mammalian DNA, 5-methylcytosine (5mC), located in gene promoters, is crucial for regulating gene expression without altering the underlying nucleotide sequence and has significantly transformed various fields of biomedical research [2].”
InfluentialAhn, R., Sabourin, V., Bolt, A. M., Hébert, S., Totten, S., Jay, N. D., Festa, M. C., Young, Y. K., Im, Y. K., Pawson, T. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14638 · Cited by 68
Epigenetic gene regulation by histone demethylases: emerging role in oncogenesis and inflammation
Kang, M., Mehrazarin, S., Park, N., & Wang, C. (2016) · Oral Diseases · doi:10.1111/odi.12569 · Cited by 68
“In fact, Peng et al (2015) reported suppression of Th1-type chemokines, CXCL9 and CXCL10, in colon cancer tissues exhibiting high expression of EZH2, SUZ12, and EED, supporting the role of PcG proteins in the silencing of inflammatory genes.”
BackgroundLevy, B. P., Giaccone, G., Besse, B., Felip, E., Garassino, M. C., Gómez, M. D., Garrido, P., Piperdi, B., Ponce-Aix, S., Menezes, D. L. D., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.028 · Cited by 63
Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice
Lai, J., Fu, Y., Tian, S., Huang, S., Luo, X., Lin, L., Zhang, X., Wang, H., Lin, Z., Zhao, H., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.005 · Cited by 65
Bashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 65
Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy
Cruickshank, B. M., Giacomantonio, M., Marcato, P., McFarland, S. A., Pol, J. G., & Gujar, S. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00654 · Cited by 63
Xu, X. J., Li, J., Zou, J., Feng, X., Zhang, C., Zheng, R., Duanmu, W., Saha-Mandal, A., Ming, Z., & Wang, E. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.9292 · Cited by 67
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Armengol, M., Santos, J. C., Fernández-Serrano, M., Profitós-Pelejà, N., Ribeiro, M. L., & Roué, G. (2021) · Cancers · doi:10.3390/cancers13020214 · Cited by 65
Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2
Christofides, A., Karantanos, T., Bardhan, K., & Boussiotis, V. A. (2016) · Oncotarget · doi:10.18632/oncotarget.12928 · Cited by 63
“These observations suggest that while inhibition of EZH2 in cancer cells can promote anti-tumor immunity by enhancing recruitment of T effector cells in the tumor microenvironment [91, 92], inhibition of EZH2 on T cells may suppress survival, expansion and efficacy of such tumor-specific effectors thereby inducing the…”
BackgroundGalow, A.-M., & Peleg, S. (2022) · Cells · doi:10.3390/cells11030468 · Cited by 66
The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy
Micevic, G., Bosenberg, M., & Yan, Q. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0784 · Cited by 63
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
Song, M., Chen, X., Wang, L., & Zhang, Y. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.01 · Cited by 63
Tumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer
Russo, E., Santoni, A., & Bernardini, G. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0320-205r · Cited by 60
Gardner, A., Pulido, Á. D. M., Hänggi, K., Bazargan, S., Onimus, A., Kasprzak, A., Conejo-Garcia, J. R., Rejniak, K. A., & Ruffell, B. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003571 · Cited by 62
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 57
“And it has been proved that epigenetic modulators can restore T cell activities and increase T cell infiltration, thus strengthening the therapeutic efficacy of PD-L1 blockade (Peng et al., 2015).”
BackgroundZhong, F., Lin, Y., Zhao, L., Yang, C., Ye, Y., & Shen, Z. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02292-0 · Cited by 61
“Patient outcome was also found to be negatively related to DNMT1 expression [80].”
BackgroundSelf-citationRegulation of immunogenic cell death and potential applications in cancer therapy
Fang, K., Yuan, S., Zhang, X., Zhang, J., Sun, S., & Li, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571212 · Cited by 67
A Mechanism of Resistance to Antibody-Targeted Immune Attack
Aldeghaither, D. S., Zahavi, D. J., Murray, J. C., Fertig, E. J., Graham, G. T., Zhang, Y., O’Connell, A., Ma, J., Jablonski, S. A., & Weiner, L. M. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0266 · Cited by 60
“A study has demonstrated that epigenetic suppression of TH1 chemokines suppresses cell trafficking to the tumor microenvironment (53).”
BackgroundEnhancing KDM5A and TLR activity improves the response to immune checkpoint blockade
Wang, L., Gao, Y., Zhang, G., Li, D., Wang, Z., Zhang, J., Hermida, L. C., He, L., Wang, Z., Si, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax2282 · Cited by 61
Self-citationPD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities
Peng, Z., Li, M., Li, H., & Gao, Q. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103666 · Cited by 68
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 70
Furudate, S., Fujimura, T., Kakizaki, A., Hidaka, T., Asano, M., & Aiba, S. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.05.004 · Cited by 60
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
Mahmoud, F. A., Shields, B. D., Makhoul, I., Avaritt, N. L., Wong, H. K., Hutchins, L. F., Shalin, S. C., & Tackett, A. J. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1323596 · Cited by 60
“EZH2 mediated H3K27 hypermethylation has been shown to repress the production of Th1- type chemokines CXCL9 and CXCL10 in the tumor resulting in low tumor infiltrating CD8C cells and poor patient outcomes in ovarian cancer, but this deserves further research in melanoma.(64) EZH2 mediated H3K27 hypermethylation may al…”
BackgroundLi, X., Zhang, Y., Chen, M., Mei, Q., Liu, Y., Feng, K., Jia, H., Dong, L., Shi, L., Liu, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1201 · Cited by 57
“2 mg/kg) treatment (21) significantly increased CD3þ T cells in the spleen and peripheral blood of mice.”
BackgroundWojcik, J. B., Marchione, D. M., Sidoli, S., Djedid, A., Lisby, A., Majewski, J., & Garcia, B. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3704 · Cited by 61
“Although, in MPNST, PRC2 loss may promote immune evasion, recent work in other tumor types suggest that, in other contexts, increased polycomb activity is associated with a suppression of immune pathways (56).”
BackgroundTargeting CXCL9/10/11–CXCR3 axis: an important component of tumor-promoting and antitumor immunity
Pan, M., Wei, X., Xiang, X., Liu, Y., Zhou, Q., & Yang, W.-B. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03126-4 · Cited by 63
“By using epigenetic modulators, this inhibitory impact can be reversed, allowing effector T cells to infiltrate the TME more efficiently [123].”
BackgroundWang, Q., Yu, M., & Zhang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1440830 · Cited by 68
Zhao, H., Ning, S., Nolley, R., Scicinski, J. J., Oronsky, B. T., Knox, S. J., & Peehl, D. M. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0312-z · Cited by 56
“In addition, Peng et al. showed that DNA methylation represses tumor production of CXCL9 and CXCL10 [25].”
BackgroundInfluentialRegulators of T‐cell fate: Integration of cell migration, differentiation and function
Groom, J. R. (2019) · Immunological Reviews · doi:10.1111/imr.12742 · Cited by 61
Desaulniers, D. M., Vasseur, P., Jacobs, A. C., Aguila, M. C., Ertych, N., & Jacobs, M. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010969 · Cited by 60
Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment
Roussot, N., Ghiringhelli, F., & Rébé, C. (2022) · Cells · doi:10.3390/cells11223672 · Cited by 59
Zhu, Q., Dai, Q., Zhao, L., Zheng, C., Li, Q., Yuan, Z., Li, L., Xie, Z., Qiu, Z., Huang, W., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06303-z · Cited by 64
Self-citationZhu, D., Zeng, S., Su, C., Li, J., Xuan, Y., Lin, Y., Xu, E., & Fan, Q. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01633-x · Cited by 63
“Peng et al. [51] discovered that DNMT1 mediates DNA methylation in OC, decreasing the synthesis of Th1-secreted chemokines CXCL9 and CXCL10, and increasing effector T-cell infiltration.”
BackgroundGou, R., Zhu, L., Zheng, M., Guo, Q., Hu, Y., Li, X., Liu, J., & Lin, B. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2023-z · Cited by 68
Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling
Nguyen, K. B., & Spranger, S. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201908224 · Cited by 59
“The immune-stimulatory changes induced in the TME dual-inhibitor treatment were highly synergistic with immunotherapeutic treatments (Peng et al., 2015).”
BackgroundThe Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors
Koustas, E., Sarantis, P., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · Biomolecules · doi:10.3390/biom10050666 · Cited by 57
“In addition, mutations in the JAK1/2 signaling pathway lead to resistance against anti-PD-1 MoAbs [87,88].”
BackgroundInfluentialTherapeutic Cancer Vaccines—T Cell Responses and Epigenetic Modulation
Kartikasari, A. E. R., Prakash, M. D., Cox, M., Wilson, K., Boer, J. C., Cauchi, J. A., & Plebanski, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03109 · Cited by 54
“For example, in ovarian cancer, tumor cell production of chemokines CXCL9 and CXCL10 are epigenetically repressed by EZH2-mediated H3K27me3 and DNMT1-mediated DNA methylation (186).”
BackgroundImmune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma
Piunti, A., Meghani, K. A., Yu, Y., Robertson, A. G., Podojil, J. R., McLaughlin, K. A., You, Z., Fantini, D., Chiang, M., Luo, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo8043 · Cited by 54
“PRC2 has been previously demonstrated to partially affect immune response in melanoma and ovarian cancer (41, 42).”
BackgroundClinical implications of tumor-intrinsic mechanisms regulating PD-L1
Prestipino, A., & Zeiser, R. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4810 · Cited by 52
“Other important oncogenic pathways in the context of cancer immunity include polycomb repressive complex 2 (PRC2) (27) and -catenin (28), for example.”
BackgroundImmunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments
Ngo, C., & Postel-Vinay, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030650 · Cited by 57
“In a nutshell, EZH2 inhibition can directly influence immunogenicity of cancer cells by (i): acting on the antigen presentation process: EZH2 expression contributes to the downregulation of Major Histocompatibility Complex (MHC)-I and MHC-II, which subsequently dampens the anti-tumor immune response [119,120]; (ii) ac…”
BackgroundRole of EZH2 histone methyltrasferase in melanoma progression and metastasis
Mahmoud, F. A., Shields, B. D., Makhoul, I., Hutchins, L. F., Shalin, S. C., & Tackett, A. J. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1167291 · Cited by 57
“cancer cells to evade immune surveillance.(15) There is a growing”
BackgroundWT1 ameliorates podocyte injury via repression of EZH2/β-catenin pathway in diabetic nephropathy
Wan, J., Hou, X., Zhou, Z., Geng, J., Tian, J., Bai, X., & Nie, J. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.03.012 · Cited by 55
“EZH2 plays a crucial role in gene expression regulation, maintenance of cell identity, stem cell renewal and oncogenesis [9,10].”
Background
Metadata
- Authors
- Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., Kotarski, J., Tarkowski, R., Dou, Y., Cho, K., Hensley-Alford, S., Munkarah, A., Liu, R., & Zou, W.
- Affiliations
- University of Michigan (US)
- Medical University of Lublin (PL)
- Henry Ford Health (US)
- Corresponding author
- Zou, Weiping
- ORCID
- Venue
- Nature
- Published
- 2015-10-26
- Volume
- 527
- Issue
- 7577
- Pages
- 249-253
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4779053
- OpenAlex
- W2103021272
- Cited by
- 1,201
- References
- 37
- Citations by year
- 2026: 79 · 2025: 100 · 2024: 104 · 2023: 132 · 2022: 155 · 2021: 159 · 2020: 125 · 2019: 109 · 2018: 85 · 2017: 89 · 2016: 61 · 2015: 2
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (CA099985, R01CA123088, R01CA152470, CA193136, R01CA156685, CA123088, 5P30 CA 46592, CA156685, CA152470, R01CA171306, R01CA193136, CA171306, R01CA099985, F31CA189440, R01CA190176, CA190176, P30CA046592)
- National Institute of General Medical Sciences (R01GM082856)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- epigenetic silencing, EZH2, DNMT1, CXCL9, CXCL10, ovarian cancer, tumor immunosuppression, adoptive T cell therapy, CD8+ T cells, H3K27me3, DNA methylation, histone modifications, tumor microenvironment, immunotherapy response
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, DNA (Cytosine-5-)-Methyltransferase 1, Animals, DNA (Cytosine-5-)-Methyltransferases, Female, Histones, Humans, Immunotherapy, Lysine, Ovarian Neoplasms, Prognosis, Tumor Cells, Cultured, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Th1 Cells, Chemokines, Tumor Escape, DNA Methylation, Gene Silencing, Xenograft Model Antitumor Assays, Epigenesis, Genetic, Mice, Chemokine CXCL10, Chemokine CXCL9, B7-H1 Antigen, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.